Peptide Therapeutics Market To Be A Game-Changer for Chronic Disease Management, says Market.us

Peptide therapeutics will be more popular due to rising cancer incidence and metabolic disorders like obesity, osteoporosis, diabetes, and other diseases. There is high demand for low-cost, efficient drugs due to the growing number of pediatric patients with target diseases and the prevalence of these conditions in low-income countries.

According to Market.us, “The Peptide Therapeutics Market is projected to reach a valuation of USD 73.50 Billion by 2032 at a CAGR of 6.3%, from USD 39.9 Billion in 2022.” 

Due to the high untapped potential, low raw material costs, a growing number of outsourcing companies, thriving biotech sector, and increased R&D investment, Asia Pacific is expected to experience significant growth. It is expected that the generic market will grow in the near future due to the lower cost of raw materials and the expiration of patents on blockbuster drugs. This could provide significant growth potential.

Anurag Sharma, a senior research analyst at Market.us, said, ” This boost can be directly attributed to higher investments in drug discovery. Research and development in peptide therapeutics are primarily focused on developing drugs for cancer, as well as metabolic disorders and infectious diseases. A strong product pipeline is expected to be one of the key factors driving the market growth. The further development of therapeutics will be supported by technological advances in peptide manufacturing.”

According to the World Health Organization (WHO), diabetes, heart disease, and cancer are the most common causes of death and disability. Effective medicines are in high demand due to the rising number of chronic diseases. This will likely drive the peptide therapy industry forward.

As therapeutics for COVID-19, advanced peptides are being developed and reconfigured. Researchers from around the globe are searching for compounds that can either prevent or reverse the effects of severe acute respiratory infection, and/or treat the complications. On February 21st, 2020, the Food and Drug Administration updated its definition of biologic to include chemically synthesized peptides containing more than 40 amino acids but less than 100 amino acid sizes and synthetic peptides containing 40 or fewer amino acids. Because peptide drugs have been recognized as potential treatments for COVID-19 and are now on the market, COVID-19 could have a positive impact on the market.

A study published in Applied Clinical Trials found that the COVID-19 global outbreak caused major disruptions in U.S. clinical trial implementation and operation between October 2020 and November 2021. It also affected key stakeholders in the healthcare industry. COVID-19 led to the relocation of key players in the healthcare sector, including manufacturers, corporate partners, and other organizations that support drug research, to remote working environments. This resulted in approximately 80% of non-COVID-19 research being stopped. COVID-19 has been deemed to have had an even greater influence on the non-COVID-19 country’s market for peptide therapy during the global pandemic.

Many companies have taken initiative to develop new drug candidates. This is expected to lead to lucrative market growth. Companies engage in extensive R&D to create novel drugs that are more effective in treating target diseases. These drugs have seen a significant increase in clinical trials over the last decade. This will also drive growth in the forecast period. Amgen and Generate Biomedicines, for example, signed a research partnership agreement in January 2022 to explore and develop protein therapeutics. This deal covers five clinical areas, as well as multiple delivery modes.

According to the World Health Organization (WHO), chronic diseases such as diabetes and cancer, along with cardiovascular diseases, are the leading causes of mortality and morbidity worldwide. Globally, chronic disease rates have risen dramatically. They affect all socioeconomic classes and all regions. In 2020, chronic diseases will account for 73 percent of all global deaths and 60 percent worldwide. The market is expected to grow due to the increasing prevalence of chronic diseases. The market’s growth will be limited by the disruption in peptide therapeutics, rising costs of developing drugs, and strict regulatory requirements for drug approval.

In-house manufacturing accounted for the highest revenue share at over 65.0% in 2021. Due to strict regulations and the high costs of outsourcing, most of the major players are involved with developing peptide therapeutics in-house. Large pharmaceutical companies are able to produce large quantities of advanced technology and have the infrastructure necessary for in-house production.

Due to the difficulty in manufacturing high-quality therapeutics, outsourcing for manufacturing is expected to increase. Companies prefer to outsource Active Pharmaceutical Ingredients (API), from companies with high-end technology, and the expertise to manufacture various types of peptides.

Peptide manufacturing can be a complicated process and requires advanced technologies like Solid-Phase Peptide Synthesis, Liquid-Phase Peptide Synthesis, and Hybrid. This allows for the purification and synthesis of high-quality products at a high cost. Market growth is expected to be driven by strategic agreements and increased R&D funding.

Peptide Therapeutics Market Key Players:

• Eli Lilly and Company
• Amgen, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Lonza Inc.
• AstraZeneca PLC
• Novartis AG